The amount of injections contained in each vial is dependent upon the dosing requirements of the animal as determined by your veterinarian
Together with the absence of symptoms associated with IGF-1-mediated effects such as fluid retention, tissue edema, or impaired glucose tolerance, these results demonstrate that AOD-9604 does not activate the growth hormone/IGF-1 pathway and therefore functions through an entirely appetite-independent mechanism

Heres what you need to know: Mechanism: Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through beta-3 adrenergic receptor modulation and direct adipocyte interaction Primary Benefit: Enhanced fat metabolism and body composition improvement without affecting blood sugar or insulin sensitivity Administration: Subcutaneous injection or oral administration, typically daily Typical Dosing: 250-500 mcg daily via injection, or higher doses (1-2 mg) orally, administered in morning on empty stomach Results Timeline: Initial metabolic changes within 2-4 weeks, visible body composition changes in 8-12 weeks Best For: Individuals seeking metabolic support, stubborn fat reduction, and body recomposition without growth hormone effects Safety Profile: Clinical trials with over 900 participants demonstrated excellent tolerability with no serious adverse events Comparison: More selective than full-length growth hormone, targeting only fat metabolism without affecting glucose regulation or IGF-1 levels The following guide provides complete details on AOD-9604 s metabolic support process, from molecular mechanisms to practical protocols

Can AHK-Cu and GHK-Cu be used together
THE WEIGHT LOSS OPTIONS ARE SO AMAZING